Travere Therapeutics shares closed at $57.36 on July 24, more than triple the $15.03 low they touched over the prior twelve months. The climb followed a second FDA approval in April, the company’s first quarter of adjusted profitability in May, and a licensing deal for an experimental kidney disease treatment in June.
A Second Use for an Existing Drug
On April 13, the Food and Drug Administration granted full approval of FILSPARI (sparsentan) for focal segmental glomerulosclerosis, or FSGS, in patients age 8 and older who do not have nephrotic syndrome. FSGS scars the kidney’s filtering units and can progress to kidney failure. Before this approval, physicians managed the disease with off-label blood-pressure drugs and immunosuppressants, since no medicine had been cleared specifically for the condition.
“Today marks a historic milestone for people living with FSGS, who for the first time have an FDA-approved medicine for this rare and devastating condition,” said Eric Dube, president and chief executive officer of Travere Therapeutics, in the company’s approval announcement.
The clearance rested on the Phase 3 DUPLEX study, the largest interventional trial conducted in FSGS, which enrolled 371 patients ages 8 to 75. Patients treated with FILSPARI saw a 46% reduction in proteinuria, a marker of kidney damage, from baseline to week 108, compared with 30% for those on irbesartan, a standard blood-pressure medicine used as the study’s comparator. Among patients without nephrotic syndrome specifically, the reduction was 48% versus 27%.
Kirk Campbell, president of the National Kidney Foundation and a professor at the University of Pennsylvania’s Perelman School of Medicine, framed the result against decades of limited options. “For decades, treatment options have been limited, often relying on off-label therapies such as long-term steroids that can carry a significant burden for patients,” Campbell said. “In the DUPLEX Study, FILSPARI delivered rapid and sustained reductions in proteinuria compared to irbesartan, with particularly meaningful effects in patients without nephrotic syndrome.”
Travere estimates the new indication expands FILSPARI’s addressable population to more than 100,000 patients in the U.S. across FSGS and IgA nephropathy, the kidney disease for which the drug first won accelerated approval in 2023 and full approval in 2024. Josh Tarnoff, chief executive officer of the patient advocacy group NephCure, called the clearance “a life-changing moment for patients and families who have waited far too long” in the company’s release.
FILSPARI carries a boxed warning for hepatotoxicity and embryo-fetal toxicity and is distributed only through a restricted program that requires prescribers, patients and pharmacies to enroll. In the DUPLEX trial, elevations in liver enzymes of at least three times the upper limit of normal occurred in up to 3.5% of treated patients, according to the FDA approval announcement, and physicians are directed to test liver function before treatment and every three months during it.
The Quarter the Losses Narrowed
The commercial effect showed up fast. Travere’s first-quarter 2026 results, released May 4, put FILSPARI’s U.S. net product sales at $105.2 million, an 88% increase over the same quarter in 2025. Total U.S. net product sales across the portfolio reached $124.5 million, up from $75.9 million a year earlier, and total revenue climbed to $127.2 million from $81.7 million.
Research and development spending rose to $57.1 million from $46.9 million, driven largely by the restart of the Phase 3 HARMONY study of pegtibatinase, an experimental treatment for classical homocystinuria. Selling, general and administrative costs rose to $80.3 million from $60.4 million as the company built out its FSGS launch infrastructure. The GAAP net loss narrowed to $37.1 million from $41.2 million. On a non-GAAP basis, the company reported net income of $4.1 million, its first quarter of non-GAAP profitability, reversing a $16.9 million non-GAAP loss in the same period a year earlier. Cash, cash equivalents and marketable securities stood at $264.7 million as of March 31.
Reaching non-GAAP profitability is a threshold most single-product commercial biotechs never cross. It does not settle the question of when, or whether, Travere reaches GAAP profitability, given the R&D and launch spending still ahead of it. But it marks a shift from a company burning cash toward one whose main product is beginning to cover its own costs.
Two other items from the quarter point toward diversification beyond FSGS and IgA nephropathy. Travere’s partner Chugai Pharmaceutical plans to submit a new drug application for sparsentan in Japan during 2026, which would extend the drug’s reach outside the U.S. market and generate milestone payments and royalties for Travere in that territory. Separately, the SPARX study, which is testing FILSPARI in post-transplant patients with recurrent IgA nephropathy or FSGS, was on track to complete enrollment in the second quarter of 2026, according to the company’s first-quarter update.
Adding a Second Drug Candidate
On June 2, Travere disclosed a licensing and collaboration agreement with Everest Medicines for civorebrutinib, also known as EVER001, an experimental oral BTK inhibitor being developed for immune-mediated kidney diseases including primary membranous nephropathy, immune-mediated FSGS and minimal change disease. Travere paid Everest $112.5 million upfront for rights in markets outside China and parts of East and Southeast Asia, with as much as $1.03 billion in additional payments tied to development, regulatory and commercial milestones across as many as five indications, plus tiered royalties on future sales.
Civorebrutinib has shown proof of concept in a Phase 1/2 trial in primary membranous nephropathy, with reported reductions in autoantibodies and proteinuria sustained through 52 weeks of follow-up, according to the companies. For a business whose value has rested almost entirely on FILSPARI, the deal adds an earlier-stage candidate in the same disease area, years away from any regulatory decision.
Institutional Holders Have Been Moving in Different Directions
Travere’s ownership base includes more than 470 institutional investors that have filed 13D, 13G or 13F disclosures with the Securities and Exchange Commission, holding roughly 118 million shares between them. Janus Henderson, BlackRock, Vanguard, Armistice Capital, Macquarie, Perceptive Advisors and State Street rank among the largest.
Filings from the back half of 2025, before the FSGS approval, show a mixed picture rather than a uniform bet on the stock. Armistice Capital’s most recent 13G amendment, filed Nov. 14, 2025, showed its Travere stake falling to 6,724,000 shares from 8,872,000, a 24% reduction that left the fund holding 7.52% of the company. BlackRock’s holding fell a similar amount over the same period, from 8,018,292 shares to 6,689,435, a 17% cut that brought its stake to 7.50%. Rock Springs Capital Management cut its position by 41%, to 2,921,196 shares, and Woodline Partners cut by 51%, to 2,114,056 shares. Point72 Asset Management’s most recent 13F, filed in November 2025, showed no remaining position, down from a prior stake. Millennium Management’s holding fell 36% in the same filing cycle.
Other institutions moved the opposite direction over the same window. Perceptive Advisors, a specialist health-care investor, more than doubled its stake to 4,895,615 shares, up 165%. Vanguard Group’s position rose nearly 20%, to 5,994,283 shares, or 6.74% of the company. Macquarie Group increased its holding by 13%, to 4,797,314 shares.
By the first quarter of 2026, after the FSGS approval and the Everest deal, Armistice’s position had shifted again. The fund’s 13F for the quarter ended March 31 showed a Travere stake of 4,897,417 shares worth roughly $145.5 million, an increase of 31% from the prior quarter and about 2.6% of Armistice’s disclosed portfolio. That made Travere the fund’s third-largest position, behind index-fund holdings tied to the S&P 500 and to 7-10 Year Treasury bonds.
The split is not unusual for a stock heading into a binary regulatory decision. Funds that build positions ahead of an FDA action are wagering on an outcome that has not yet happened. Many trim or exit once that uncertainty resolves, regardless of which way it resolves. Others wait instead. They let the approval de-risk the story first, which can mean adding into a stock only after much of the initial move has already occurred. Travere’s shareholder register through this period shows both patterns at once, rather than a single consensus view moving in one direction.
What the Market Has Priced In So Far
Sell-side price targets have moved with the stock. Citi raised its target from $59 to $62 after the Everest deal in June, then to $70 by late July. Guggenheim lifted its target to $65 from $56 and Wedbush raised its target to $61 from $55 over the same stretch, according to research notes tracked by StockAnalysis.com. As of late July, the average 12-month price target across covering analysts stood at roughly $58.71, according to the same data, modestly above the stock’s trading level. That gap reflects a stock that has already absorbed much of the good news from the approval, the earnings report and the licensing deal, with analysts divided on how much further the story has to run. None of this activity constitutes investment advice, and institutional positioning of the kind on display among Travere’s shareholder base can reverse as quickly as it built.
